ERBB2 and triple-negative breast carcinoma: Our study was the first to describe lower levels of ADAMTS-1 protein in triple-negative breast cancer cases (ER-, PR-, and Her-2), and our immunoblot analyses indicated that ADAMTS-1 expression was reduced in tumors in comparison to contralateral normal tissues.